Mast cell leukemia medical therapy
Mast cell leukemia Microchapters
Mast cell leukemia medical therapy On the Web
American Roentgen Ray Society Images of Mast cell leukemia medical therapy
Risk calculators and risk factors for Mast cell leukemia medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. ;Associate Editor(s)-in-Chief: Nawal Muazam M.D.
The mainstay of therapy for symptomatic mast cell leukemia patients is immunochemotherapy.
Therapeutic approaches are limited and consist of reducing the tumor burden and conservation of organ functions.
- Corticosteroids have been recommended as a short term use in combination with cytotoxic drugs.
- It could also be beneficial in some situations such as:
Interferon-α reduces the frequency of:
- Histamine related attacks
- Decrease bone marrow infiltration by mast cells
- Decrease liver infiltration by mast cells
- Decrease skin manifestations
- Improve osteoporosis
2-Chloro-deoxy-adenosine has a potential value in the treatment of mast cell leukemia with symptomatic responses and improvement in mast cell variables.
Cladribine has been used in rare cases of mast cell leukemia with relatively small or no efficacy.
Imatinib does not have direct effect on the D816V KIT mutation, but it may affect other sporadic mutations.
Dasatinib demonstrates significant inhibitory activity against WT KIT as well as juxtamembrane domain mutant KIT. This activity has been proven in patients negative for D816V KIT.
Nilotinib displays also equipotent activity to imatinib in D816V c-KIT negative patients.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Georgin-Lavialle, S.; Lhermitte, L.; Dubreuil, P.; Chandesris, M.-O.; Hermine, O.; Damaj, G. (2012). "Mast cell leukemia". Blood. 121 (8): 1285–1295. doi:10.1182/blood-2012-07-442400. ISSN 0006-4971.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Joris, Magalie; Georgin-Lavialle, Sophie; Chandesris, Marie-Olivia; Lhermitte, Ludovic; Claisse, Jean-François; Canioni, Danielle; Hanssens, Katia; Damaj, Gandhi; Hermine, Olivier; Hamidou, Mohammed (2012). "Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive". Case Reports in Hematology. 2012: 1–6. doi:10.1155/2012/517546. ISSN 2090-6560.